Intracellular collagen degradation mediated by uPARAP/Endo180 is a major pathway of extracellular matrix turnover during malignancy by Curino, Alejandro C. et al.
T
H
E
J
O
U
R
N
A
L
O
F
C
E
L
L
B
I
O
L
O
G
Y
 
JCB: ARTICLE
 
The Journal of Cell Biology, Vol. 169, No. 6, June 20, 2005 977–985
http://www.jcb.org/cgi/doi/10.1083/jcb.200411153
 
JCB 977
 
Intracellular collagen degradation mediated by 
uPARAP/Endo180 is a major pathway of 
extracellular matrix turnover during malignancy
 
Alejandro C. Curino,
 
1
 
 Lars H. Engelholm,
 
4
 
 Susan S. Yamada,
 
3
 
 Kenn Holmbeck,
 
3
 
 Leif R. Lund,
 
4
 
 Alfredo A. Molinolo,
 
2
 
 
Niels Behrendt,
 
4
 
 Boye Schnack Nielsen,
 
4
 
 and Thomas H. Bugge
 
1
 
1
 
Proteases and Tissue Remodeling Unit and 
 
2
 
Molecular Carcinogenesis Unit, Oral and Pharyngeal Cancer Branch, and 
 
3
 
Matrix Metalloproteinase Unit, Craniofacial and 
Skeletal Diseases Branch, National Institute of Dental and Craniofacial Research, National Institutes of Health, Bethesda, MD 20892
 
4
 
Finsen Laboratory, Rigshospitalet, DK-2100 Copenhagen Ø, Denmark
 
e recently reported that uPARAP/Endo180
can mediate the cellular uptake and lysoso-
mal degradation of collagen by cultured ﬁ-
broblasts. Here, we show that uPARAP/Endo180 has a
key role in the degradation of collagen during mammary
carcinoma progression. In the normal murine mammary
gland, uPARAP/Endo180 is widely expressed in periduc-
tal ﬁbroblast-like mesenchymal cells that line mammary
epithelial cells. This pattern of uPARAP/Endo180 expres-
sion is preserved during polyomavirus middle T–induced
W
 
mammary carcinogenesis, with strong uPARAP/Endo180
expression by mesenchymal cells embedded within the col-
lagenous stroma surrounding nests of uPARAP/Endo180-
negative tumor cells. Genetic ablation of uPARAP/
Endo180 impaired collagen turnover that is critical to tu-
mor expansion, as evidenced by the abrogation of cellular
collagen uptake, tumor ﬁbrosis, and blunted tumor growth.
These studies identify uPARAP/Endo180 as a key mediator
of collagen turnover in a pathophysiological context.
 
Introduction
 
Malignant progression is an example of a radical tissue remod-
eling process in which one tissue (normal tissue) is invaded and
is eventually completely substituted by a different tissue (tumor
tissue). The process is characterized by dramatic increases in
both the rate of synthesis and the rate of turnover of ECM com-
ponents in a complex cycle of continuous ECM deposition and
degradation. ECM degradation serves at least four different
functions that all are essential to tumor progression. It facilitates
the physical expansion of the tumor mass, liberates latent tumor
growth factors embedded within the ECM, enables the forma-
tion of a neovasculature within the expanding tumor mass, and
subverts the proliferative restrictions imposed on tumor cells
by ECM (Hotary et al., 2003; Mott and Werb, 2004). Inhibition
of ECM degradation has, therefore, long been recognized as an
attractive target for therapeutic intervention aimed at limiting
tumor growth (Coussens and Werb, 2002).
The degradation of ECM during malignant progression is
a proteolytic event. Because most tumor cell lines produce in-
creased levels of proteases, ECM degradation was initially
believed to be a relatively simple process that was executed
directly by tumor cells through the secretion of an assortment
of ECM-degrading proteases (Liotta et al., 1980, 1991; Danø et
al., 1985). However, an exhaustive body of work that now
spans more than two decades has demonstrated a much higher
level of complexity. Thus, the current paradigm holds that
ECM degradation during malignant progression is the result
of a finely coordinated interplay between tumor cells, tumor-
associated stromal cells, and tumor-infiltrating inflammatory
cells, each having distinct and indispensable roles in the pro-
cess. Furthermore, this work has identified the tumor stromal
cell as one of the principle mediators of ECM turnover during
tumor invasion. As such, malignant progression may show
striking similarities to a variety of normal physiological tissue
remodeling processes (Danø et al., 1999; Werb et al., 1999;
Liotta and Kohn, 2001).
Collagens are the most abundant ECM components in the
body and are a universal part of the tumor ECM (Hanahan and
Weinberg, 2000; Liotta and Kohn, 2001; Chambers et al.,
2002). They consist of three polypeptide chains, each with a
single, long uninterrupted section of Gly-X-Y repeats that are
intertwined to produce a superhelix that buries the peptide
bonds within the interior of the helix. The fibrillar collagens
spontaneously self associate to form fibrils that range in diameter
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from 10 to 300 nm, whereas basement membrane collagens
form complicated sheets with both triple helical and globular
motifs (van der Rest and Garrone, 1991). The unique supramo-
lecular organization makes fibrillar collagens relatively resis-
tant to proteolytic degradation. However, several molecular
pathways that are involved in the turnover of collagen in nor-
mal physiological processes have been identified. One pathway
involves a group of secreted or membrane-associated matrix
metalloproteases (collagenases) and is believed to take place
within the pericellular/extracellular environment. A second ca-
thepsin-mediated pathway that is specific for bone resorption
takes place in the acidic microenvironment that is created at the
osteoclast/osteoid interface (Gelb et al., 1996; Saftig et al.,
1998). A third pathway is intracellular and involves the binding
of collagen fibrils to specific cell surface receptors, followed
by the cellular uptake and proteolytic degradation of inter-
nalized collagen in the lysosomal compartment (Everts et
al., 1996). The contributions of pericellular/extracellular pro-
teolytic pathways to collagen degradation during tumor pro-
gression are documented in numerous studies (Mott and Werb,
2004). In sharp contrast, the functional involvement of the in-
tracellular collagen degradation pathway to this important
pathophysiological process is unexplored to date.
uPARAP/Endo180 is a newly discovered member of the
macrophage mannose receptor family of endocytic transmem-
brane glycoproteins. The receptor is highly expressed by cer-
tain mesenchymal cells that are located at sites of active tissue
remodeling, including human cancer (Schnack Nielsen et al.,
2002). By gene targeting in mice, we recently identified a criti-
cal role of uPARAP/Endo180 in the cellular uptake and lysoso-
mal degradation of collagen (Engelholm et al., 2003; Kjøller et
al., 2004). We now have taken advantage of the availability of
these mutant mice with a defect in intracellular collagen degra-
dation to determine the functional contribution of this pathway
to collagen turnover in cancer by using a validated murine
model of ductal mammary adenocarcinoma (Guy et al., 1992;
Maglione et al., 2001; Lin et al., 2003). We report that intracel-
lular collagen degradation by tumor stromal cells is a func-
tionally relevant pathway for collagen turnover during malig-
nant progression, and this process is meditated by uPARAP/
Endo180. This finding has important implications for the un-
derstanding of ECM turnover in cancer.
 
Results
 
uPARAP/Endo180 expression in 
polyomavirus middle T (PymT)–induced 
mammary adenocarcinoma mimics 
expression in human mammary cancer
 
We have previously shown that uPARAP/Endo180 expression
is limited in the normal human mammary gland, but the recep-
tor becomes highly expressed by mesenchymal stromal cells
during mammary tumorigenesis (Schnack Nielsen et al., 2002).
To determine if the expression of uPARAP/Endo180 in PymT-
induced ductal mammary adenocarcinoma resembles the ex-
pression pattern observed in the human disease, we first per-
formed an immunohistochemical analysis of the normal murine
mammary gland and PymT-induced mammary tumors. As
a control for antibody specificity, we included uPARAP/
Endo180-deficient mammary glands and tumors in the analy-
sis. uPARAP/Endo180 expression in the resting virgin mouse
mammary gland was detected in fibroblast-like cells lining the
periphery of mammary ducts, in connective tissue trabeculae
encapsulating the gland, and dispersed within adipose tissue
(Fig. 1 A and not depicted). This expression pattern was faith-
fully maintained throughout PymT-induced mammary tumor
progression, with strong uPARAP/Endo180 immunoreactivity
in fibroblast-like cells embedded within the collagenous stroma
surrounding or adjacent to nests of tumor cells (Fig. 1, B and
C). Like human mammary cancer, the tumor cells were uPARAP/
Endo180-negative at all analyzed stages (Fig. 1, B and C). The
identical pattern of expression of uPARAP/Endo180 mRNA in
normal and malignant mammary glands was observed by in
situ hybridization (Fig. 1, E and F; and not depicted). Together,
these data show that uPARAP/Endo180 expression during
PymT-induced mammary carcinogenesis in mice resembles the
previously established pattern of expression in the human
mammary gland and human mammary cancer and validates the
PymT model as suitable for functional studies of uPARAP/
Endo180.
 
uPARAP/Endo180 mediates collagen 
uptake and degradation by tumor 
stromal cells during mammary tumor 
progression
 
To determine the functional relevance of stromal uPARAP/
Endo180 in mammary cancer, we took advantage of the avail-
ability of recently generated uPARAP/Endo180-deficient mice.
These mice are viable and fertile and display good health in the
absence of external challenges or additional genetic defects
in collagenolytic pathways (Engelholm et al., 2003). The
uPARAP/Endo180-deficient mice were first extensively back-
crossed to FVB mice and were subsequently interbred with
FVB-PymT mice to generate mice that developed mammary
tumors in the presence and absence of uPARAP/Endo180. To
study cellular collagen turnover within PymT-induced mam-
mary tumors, we first explanted uPARAP/Endo180-sufficient
and -deficient tumors ex vivo by using a modification of previ-
ously established procedures that allow the short term coculture
of mammary tumor cells with their associated tumor stromal
cells (Pandis et al., 1992; Dran et al., 1995; Lanari et al., 2001).
The explants spontaneously organized as epithelial sheets of
tightly clustered tumor cells that were surrounded by larger
mesenchymal cells with a typical fibroblast morphology (Fig.
2 A). Oregon green–conjugated collagen fibrils were added to
the explants, and the fate of the labeled collagen was studied by
confocal fluorescence microscopy in the presence of the cys-
teine protease inhibitor E64d, which blocks lysosomal degrada-
tion of collagen (Kjøller et al., 2004). 8 h after the addition of
collagen, the majority of labeled collagen was located within
vesicular structures of the stromal cells of uPARAP/Endo180-
sufficient explants (Fig. 2 B). Confocal fluorescence micros-
copy analysis showed that a subset of these collagen-containing
vesicles of predominantly perinuclear localization were also 
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stained with LysoTracker, a specific marker for lysosomes,
suggesting that collagen was targeted for lysosomal degrada-
tion after the initial uptake by tumor stromal cells (Fig. 2 B).
This cellular association was exclusively confined to the stro-
mal fibroblast-like cells, with no tumor cell–associated col-
lagen being apparent, as judged by visualization of the tumor
cells with cytokeratin antibodies (Fig. 2 D). In striking contrast,
in uPARAP/Endo180-deficient tumor explants, the collagen re-
mained extracellular and formed fiberlike structures that were
located in close proximity to the stromal cells (Fig. 2 C). To
study collagen internalization in uPARAP/Endo180-sufficient
and -deficient explants in greater detail, a time course study
was used. Oregon green–conjugated collagen fibrils were
added to the explants at 4
 
 
 
C to permit cell surface binding but
not internalization of the collagen, and, thereafter, unbound
collagen was removed by washing. At this time point, confocal
analysis showed a mostly diffuse localization of the labeled
collagen and occasionally showed poorly organized fiberlike
structures (Fig. 2, E and F). A similar distribution has been de-
scribed after the addition of collagen fibrils to cultured dermal
fibroblasts at 4
 
 
 
C (Kjøller et al., 2004). Collagen internaliza-
tion was initiated by raising the temperature of the explants to
37
 
 
 
C. After 2 h, the labeled collagen was associated with the
surface of cells in explants from both genotypes, with small
amounts of collagen appearing in intracellular vesicles of
uPARAP/Endo180-sufficient (Fig. 2 G), but not uPARAP/
Endo180-deficient, explants (Fig. 2 H). After 4 h, most of the
collagen that was added to uPARAP/Endo180-sufficient ex-
plants was located in intracellular vesicles, frequently located
in lysosomes (as judged by colocalization with LysoTracker),
with smaller amounts in fiberlike extracellular structures (Fig.
2 I). At this time point, collagen remained in extracellular fiber-
like structures of uPARAP/Endo180-deficient explants, gener-
ally displaying a greater organization compared with 2 h after
the temperature shift (Fig. 2 J). Altogether, the data show that
tumor stromal cells mediate the time-dependent cellular uptake
and intracellular degradation of collagen in primary mammary
tumor explants and that this process is strictly uPARAP/
Endo180 dependent.
Next, the uPARAP/Endo180-dependent cellular uptake
of collagen by PymT-induced mammary tumors was analyzed
by transmission electron microscopy of uPARAP/Endo180-
deficient and -sufficient tumors that were excised directly from
95–105-d-old mice. In uPARAP/Endo180-sufficient tumors,
prominent intracellular membrane–bordered collagen inclu-
sions were present in cells with an ultrastructural morphology
compatible with fibroblasts. The intracellular collagen pre-
sented as transected bundles of fibrils or longitudinally dis-
sected fibrils with typical periodicity, often located close to the
nucleus (Fig. 2 K and not depicted). These collagen inclusions
were morphologically similar to phagocytosed collagen inclu-
sions, which were described previously in fibroblasts associ-
Figure 1. uPARAP/Endo180 is expressed in fibro-
blast-like stromal cells of the normal murine mammary
gland and mammary tumors. (A) Immunohistochemical
staining of normal virgin mammary gland showing
expression of uPARAP/Endo180 in fibroblast-like
mesenchymal cells lining the periphery of mammary
ducts (arrow) and fibroblast-like cells embedded in
adipose tissue (arrowheads), but not in mammary epi-
thelial cells (curved arrow). (B) Mammary intraepithe-
lial neoplasia in a 5-wk-old PymT female mouse show-
ing periductal expression of uPARAP/Endo180 in
fibroblast-like mesenchymal cells (arrows), but ab-
sence of uPARAP/Endo180 expression in mammary
tumor cells (stars). (C) Advanced mammary carci-
noma in a 13-wk-old PymT mouse showing uPARAP/
Endo180 expression in fibroblast-like cells in connec-
tive tissue streaks transecting tumors (arrows), and ab-
sence of uPARAP/Endo180 expression in mammary
tumor cells (star). (D) Absence of immunoreactivity in
a tumor from a 13-wk-old PymT/uPARAP/Endo180
 / 
mouse stained in parallel demonstrates the specificity
of the immunostaining procedure for uPARAP/
Endo180. Brightfield (E) and darkfield (F) images of
in situ hybridization using a uPARAP antisense probe
of a mammary tumor from a 15-wk-old mouse, dem-
onstrating the identical distribution of uPARAP/
Endo180 mRNA and antigen, with uPARAP/
Endo180 mRNA in stromal cells (arrowheads) adja-
cent to nests of uPARAP/Endo180 mRNA-negative
tumor cells (stars). Bars, 50  m. 
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ated with rheumatoid arthritis in humans or experimentally in-
duced polyarthritis in rats and in lung macrophages during
experimental emphysema (Cullen, 1972; Neurath, 1993; Lucat-
telli et al., 2003). In striking contrast, a survey of 56 sections
from three uPARAP/Endo180-deficient tumors showed ab-
sence of intracellular collagen (Fig. 2 L). When combined,
the data support the notion that the cellular uptake of col-
lagen in mammary tumors is mediated by a uPARAP/
Endo180-dependent pathway.
 
uPARAP/Endo180 deficiency initiates 
mammary tumor fibrosis
 
The contribution of stromal uPARAP/Endo180 to collagen
turnover during mammary tumor progression was determined
by analyzing collagen accumulation in mammary tumors from
uPARAP/Endo180-deficient FVB-PymT
 
 
 
 virgin females and
isogenic uPARAP/Endo180-sufficient FVB-PymT
 
 
 
 virgin fe-
male littermates. Immunohistochemical staining of tumors
from 105-d-old mice revealed a striking increase in both inter-
stitial (type I) and basement (type IV) collagen in uPARAP/
Endo180-deficient animals, which was immediately evident by
microscopic inspection (Fig. 3, A–D) and could be quantita-
tively documented by histomorphometric analysis (Fig. 3 K).
In contrast, fibronectin (Fig. 3, E and F), which is internalized
by mesenchymal cells in a uPARAP/Endo180-independent
manner (Engelholm et al., 2003), and the collagen-associated
ECM proteins decorin (Fig. 3, G and H) and nidogen (Fig. 3, I
and J) did not display significantly increased accumulation in
uPARAP/Endo180-deficient tumors. The significant increase
in tumor collagen was not caused by an increase in collagen
synthesis, as shown by Northern blot analysis of collagen
Col1A1 and Col4A1 mRNA (Fig. 3 L) or immunohistochemical
Figure 2. uPARAP/Endo180 mediates cellular
collagen uptake in mammary tumors. (A) Phase-
contrast micrograph of explanted uPARAP/
Endo180
  mammary tumors showing sponta-
neous organization of tightly clustered sheets
of small epithelial tumor cells (star) surrounded
by larger mesenchymal cells with a typical fi-
broblast morphology. (B and C) Representative
confocal fluorescence images of explants of
mammary tumors from uPARAP/Endo180
  (B)
and littermate uPARAP/Endo180
 /  (C) mice
8 h after the addition of Oregon green–conju-
gated collagen fibrils to the explant medium.
Explants were stained with LysoTracker (red)
for the visualization of lysosomes and DAPI
(blue) for the visualization of nuclei. uPARAP/
Endo180
  tumor explants display the uptake
of fluorescence-labeled collagen (green) into
vesicles of large mesenchymal, fibroblast-like
stromal cells located adjacent to mammary
tumor cell clusters. Targeting of collagen to
lysosomes is shown by the colocalization of
green and red fluorescence (B, yellow) in
some perinuclear vesicles. In sharp contrast to
uPARAP/Endo180
  explants, collagen de-
posits in extracellular fiberlike structures in
uPARAP/Endo180
 /  mammary tumor ex-
plants. (D) Confocal fluorescence images after
labeling of tumor cells with cytokeratin anti-
bodies (red) shows the absence of internal-
ized collagen in tumor cells. (E–J) Time course
analysis of collagen internalization in uPARAP/
Endo180
  (E, G, and I) and uPARAP/
Endo180
 /  explants (F, H, and J) using Ore-
gon green–conjugated collagen fibrils and
LysoTracker for visualization of lysosomes. Dif-
fuse localization of collagen with occasional
fiberlike structures immediately after collagen
addition (E and F). Increased cellular associa-
tion after 2 h, with some collagen in intracellu-
lar vesicles in uPARAP/Endo180
  explants
(G), but not in uPARAP/Endo180
 /  explants
(H). (I) Predominant localization of collagen in
intracellular vesicles of stromal cells of uPARAP/
Endo180
  explants at 4 h, frequently colocal-
izing with LysoTracker-positive vesicles with
perinuclear locations, versus the location of
collagen in extracellular fiberlike structures
with an increasing degree of organization compared with those after 2 h in uPARAP/Endo180
 /  explants (J). (K and L) Representative examples of high
magnification transmission electron micrographs of mammary tumor stromal cells from 105-d-old mice showing intracellular collagen inclusion (star) that is
adjacent to the nucleus of a uPARAP/Endo180
  fibroblast (K) and the exclusively extracellular localization of collagen (star) in uPARAP/Endo180
 / 
tumors (L). Arrows (L) show the position of the plasma membrane. Bars: (B–J) 40  m; (K and L) 500 nm. 
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staining with collagen I propeptide antibodies (not depicted).
Gelatin zymography (Fig. 3 M, top) and reverse zymography
(Fig. 3 M, bottom) showed abundant and variable levels of col-
lagenase/gelatinase, MMP-2, gelatinase, MMP-9, and TIMP-2,
which did not correlate with the uPARAP/Endo180 status.
Likewise, uPARAP/Endo180 deficiency did not alter the ex-
pression of the collagenases MT1-MMP and MMP-13 (Fig. 3,
N–U). Altogether, these findings point to a direct and quan-
titatively relevant role of uPARAP/Endo180 in mediating cel-
lular uptake and lysosomal degradation of collagen during
mammary tumor progression. Besides fibroblasts, uPARAP/
Endo180 has been reported to be expressed on tumor endothe-
lial cells and macrophages, invoking a potential function of the
receptor for the functionality of the two cell types within the tu-
mor environment (Sheikh et al., 2000; St Croix et al., 2000).
However, uPARAP/Endo180 deficiency did not appear to im-
pair either tumor vascularization, as judged by the density of
CD31-positive vessels, or macrophage accumulation, as judged
by the number of F4/80-positive cells (vessels per 100 cells:
uPARAP/Endo180
 
 
 
/PymT
 
 
 
, 4.0 
 
 
 
 0.6 [
 
n 
 
  
 
5 tumors];
uPARAP/Endo180
 
 
 
/
 
 
 
/PymT
 
 
 
, 3.7 
 
 
 
 0.3 [
 
n
 
 
 
  
 
5 tumors], P 
 
 
 
NS. Macrophages per 100 cells: uPARAP/Endo180
 
 
 
/PymT
 
 
 
,
1.6 
 
 
 
 0.3 [
 
n
 
 
 
  
 
5 tumors]; uPARAP/Endo180
 
 
 
/
 
 
 
/PymT
 
 
 
, 2.0 
 
 
 
0.6 [
 
n 
 
  
 
5 tumors], P 
 
 
 
 NS).
A recent study has implicated the rate of turnover of
three-dimensional collagen matrices as a critical regulator of
tumor cell proliferation (Hotary et al., 2003). To determine the
effect of increased collagen deposition caused by uPARAP/
Figure 3. Collagen accumulation in uPARAP/Endo180-deficient mammary tumors. Representative examples of the appearance of uPARAP/Endo180
 
tumors (A, C, E, G, and I) and uPARAP/Endo180
 /  tumors (B, D, F, H, and J) after immunohistochemical staining for collagen type I (A and B), type IV
(C and D), fibronectin (E and F), decorin, (G and H), and nidogen (I and J). uPARAP/Endo180
 /  tumors display an obvious accumulation of collagen in
the tumor stroma (arrowheads) surrounding nests of tumor cells (A–D, arrows), whereas no significant changes are apparent in fibronectin, nidogen, or
decorin deposition (arrowheads) around tumor cell nests (E–J, arrows). (K) Histomorphometric quantitation of collagen I, collagen IV, fibronectin, nidogen,
and decorin accumulation in uPARAP/Endo180
  (crosshatched bars) and uPARAP/Endo180
 /  (shaded bars) tumors. (L) Northern blot analysis of
Col1A1 and Col4A1 mRNA in uPARAP/Endo180
  (crosshatched bars) and uPARAP/Endo180
 /  (shaded bars) tumors. Signal intensities were deter-
mined by PhosphorImage analysis and normalized to the GAPDH mRNA signal intensity. Error bars indicate SEM. (M) Gelatin zymography (top) of extracts
of uPARAP/Endo180
  (lanes 1–3) and uPARAP/Endo180
 /  tumors (lanes 4–6), and reverse zymography (bottom) showing amounts of zymographically
active MMP-2, MMP-9, and TIMP-2. The position of lysis zones generated by MMP-2 and active MMP-9 and zones of inhibition of lysis by TIMP-2 are in-
dicated at left. The positions of molecular mass markers (kD) are indicated at right. (N–U) Representative examples of in situ hybridization of MT1-MMP
(N, O, R, and S) and MMP-13 (P, Q, T, and U) mRNA expression in uPARAP/Endo180
 /  tumors (N–Q) and uPARAP/Endo180
  tumors (R–U) using 
32P-
labeled antisense probes and complementary sense probes. Specific hybridization signals in uPARAP/Endo180-sufficient and -deficient tumors are observed
in stromal cells (arrowheads) surrounding nests of tumor cells (arrows). Six tumors were analyzed for each of the two MMPs. Bars: (A–J) 500  m; (N–U) 100  m.
All p-values were determined by a two-tailed t test. 
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Endo180 deficiency on tumor cell proliferation, proliferative
indices of uPARAP/Endo180-deficient and -sufficient tumors
were determined by BrdU incorporation. This experiment
showed no appreciable difference in the rate of proliferation of
uPARAP/Endo180-sufficient and -deficient tumors, suggesting
that the increased accumulation of collagen in uPARAP/
Endo180-deficient tumors does not significantly impair tumor
cell proliferation (percentage of BrdU-incorporating cells:
uPARAP/Endo180
 
 
 
/PymT
 
 
 
, 6.5 
 
 
 
 2.4 [
 
n 
 
  
 
5 tumors]; uPARAP/
Endo180
 
 
 
/
 
 
 
/PymT
 
 
 
, 6.6 
 
 
 
 2.7 [
 
n 
 
  
 
5 tumors], P 
 
 
 
 NS). Fur-
thermore, we also did not observe a trend toward an increased
rate of tumor cell apoptosis, as measured by TUNEL staining
(percentage of apoptotic cells: uPARAP/Endo180
 
 
 
/PymT
 
 
 
,
0.7 
 
 
 
 0.3 [
 
n 
 
  
 
3 tumors]; uPARAP/Endo180
 
 
 
/
 
 
 
/PymT
 
 
 
, 0.8 
 
 
 
0.2 [
 
n 
 
  
 
3 tumors], P 
 
 
 
 NS).
 
uPARAP/Endo180 promotes mammary 
tumor growth
 
We next determined the direct impact of the loss of uPARAP/
Endo180 on mammary tumor growth. For this purpose, cohorts
of uPARAP/Endo180-deficient FVB-PymT
 
 
 
 virgin females
and isogenic uPARAP/Endo180-sufficient FVB-PymT
 
 
 
 virgin
female littermates and siblings were generated and monitored
for mammary tumor development. No differences were ob-
served in the initial rate of formation of palpable mammary tu-
mors or in the mean number of tumors that formed in the mice,
showing that uPARAP/Endo180 is not essential for tumorigen-
esis (mean tumor latency: uPARAP/Endo180
 
 
 
/
 
 
 
/PymT
 
 
 
, 48 d
[
 
n
 
 
 
  
 
47 mice]; uPARAP/Endo180
 
 
 
/PymT
 
 
 
, 47 d [
 
n 
 
   48
mice], P   NS. All of the 49 uPARAP/Endo180
  and 41
uPARAP/Endo180
 /  mice had tumors in all mammary glands
at 105 d). Interestingly, however, despite the prominent accu-
mulation of collagen in the uPARAP/Endo180-deficient tu-
mors, the size of the tumors was significantly diminished rather
than increased (Fig. 4). This diminution of tumor growth in
uPARAP/Endo180-deficient tumors was evident at both 95 (Fig.
4 A) and 105 d of age (Fig. 4 B), as determined by the accumu-
lated tumor burden of postmortem excised tumors from two in-
dependent cohorts of littermate uPARAP/Endo180-deficient
and -sufficient mice (95 d of age: mean tumor burden of
uPARAP/Endo180
 /PymT
 , 9.2 g, range 5.2–16.8 g [n   19
mice]; uPARAP/Endo180
 / /PymT
 , 6.6 g, range 3.4–11.0 g
[n   18 mice], P   0.0061, t test; P   0.0093, Wilcoxon rank
sum test. 105 d of age: uPARAP/Endo180
 /PymT
 , 15.1 g,
range 6.6–26.4 g [n     48 mice]; uPARAP/Endo180
 / /
PymT
 , 11.5 g, range 5.0–20.6 g [n   41 mice], P   0.00024,
t test; P   0.00065, Wilcoxon rank sum test).
In summary, the studies presented here suggest that
uPARAP/Endo180-dependent intracellular collagen degrada-
tion is functionally important to mammary tumor growth.
Discussion
uPARAP/Endo180 is a collagen internalization receptor that
is expressed exclusively on mesenchymal cells, and its asso-
ciation with human epithelial tumors stems from its consis-
tent and dramatic overexpression by mesenchymal cells em-
bedded within the supporting tumor stroma rather than from
its expression by tumor cells (St Croix et al., 2000; Schnack
Nielsen et al., 2002). In this paper, we investigated the spe-
cific functions of stromal uPARAP/Endo180 in tumorigene-
sis by using a validated mouse model of human ductal mam-
mary adenocarcinoma (Maglione et al., 2001; Lin et al.,
2003). Our results show that intracellular collagen degrada-
tion is a quantitatively relevant pathway for the turnover of
collagen during tumor progression. The data also show that
this process is mediated by uPARAP/Endo180. Tumors de-
prived of uPARAP/Endo180 displayed an abrogation of cel-
lular collagen uptake, a fibrotic state characterized by the
accumulation of both basement membrane and interstitial col-
lagens, and an overall tumor size reduction, despite the col-
lagen accumulation.
Figure 4. uPARAP/Endo180 promotes mam-
mary tumor progression. Scatter plots of the cu-
mulative tumor burdens of uPARAP/Endo180
 
(open circles) and uPARAP/Endo180
 /  (filled
circles) mice at 95 (A) and 105 d of age (B),
as determined by postmortem measurement of
the weight of excised mammary tumors. Hori-
zontal bars indicate mean values. P-values de-
termined by a two-tailed t test and a Wilcoxon
rank  sum test are shown. N indicates the
number of mice analyzed.INTRACELLULAR COLLAGEN DEGRADATION IN CANCER • CURINO ET AL. 983
A previous study has shown that MT1-MMP–dependent
pericellular collagen degradation is a critical regulator of tumor
cell proliferation (Hotary et al., 2003). A direct impairment of
tumor cell proliferation caused by the lack of uPARAP/
Endo180-dependent intracellular collagen degradation and the
associated accumulation of interstitial and basement membrane
collagen, therefore, suggested a plausible explanation for the
impaired tumor growth in uPARAP/Endo180-deficient mice.
However, despite pronounced differences in collagen deposi-
tion, proliferation rates were similar in uPARAP/Endo180-suf-
ficient and -deficient tumors. Furthermore, no appreciable dif-
ferences were detected in the rate of apoptosis. The specific
mechanism by which uPARAP/Endo180-dependent collagen
turnover promotes mammary tumor progression, therefore, re-
mains to be determined.
The extracellular/pericellular MMP-dependent pathway
of collagen turnover has been extensively studied and has been
the target of clinical cancer trials in humans (McCawley and
Matrisian, 2000; Coussens and Werb, 2002; Mott and Werb,
2004). In contrast, the functional relevance of intracellular col-
lagen turnover to tumor progression in vivo was essentially
undefined before this study, owing largely to the inability to
experimentally manipulate the process; this obstacle was over-
come with the generation of uPARAP/Endo180-deficient mice
(Engelholm et al., 2001a; East et al., 2003). Because of the data
presented in this paper, it can now be concluded that intracellu-
lar collagen degradation is both functionally relevant to col-
lagen turnover in cancer and also represents an important path-
way of turnover of this, the most abundant of the ECM
components. The expression of uPARAP/Endo180 in human
cancer is still under investigation (Behrendt, 2004). It is note-
worthy, however, that the receptor has been found to be ex-
pressed in the stroma of all human carcinomas investigated to
date (St Croix et al., 2000; Schnack Nielsen et al., 2002). More-
over, uPARAP/Endo180 expression has been reported also at
sites of nonneoplastic tissue degenerative diseases such as os-
teoarthritis (Howard et al., 2004), and intracellular inclusions of
phagocytosed collagen have been demonstrated in mesenchy-
mal cells associated with periodontal disease, emphysema, and
rheumatoid arthritis (Cullen, 1972; Harris et al., 1977; Soames
and Davies, 1977; Neurath, 1993; Lucattelli et al., 2003). Alto-
gether, these findings imply that uPARAP/Endo180 could have
a generalized role in collagen turnover during human cancer
progression as well as in other chronic tissue destructive dis-
eases and, thus, could serve as a novel therapeutic target.
The functional relationship between extracellular MMP-
dependent and intracellular uPARAP/Endo180-dependent col-
lagenolysis remains to be elucidated. Of particular importance
will be to study the possible prerequisite for fibrillar collagen
cleavage before its interaction with uPARAP/Endo180. The
currently available evidence tentatively suggests that the cellu-
lar uptake of collagen by uPARAP/Endo180 is independent of
the prior cleavage of collagen by MMPs. First, the cellular up-
take of fibrillar collagen by mesenchymal cells has been re-
ported to be insensitive to MMP inhibition (Everts et al., 1989).
Second, MT1-MMP–deficient mice, which display a severe
impairment of fibrillar collagen degradation, present a dramatic
compensatory increase in collagen phagocytosis by mesenchy-
mal cells (Holmbeck et al., 1999; Szabova et al., 2005). Third,
preliminary studies of mice with a combined deficiency in in-
tracellular collagen degradation (uPARAP/Endo180
 / ) and
extracellular collagen degradation (Col1A1r/r or MT1-MMP
 / )
reveal a more profound collagen remodeling defect than mice
with individual deficiencies (unpublished data). Together,
these data suggest that extracellular and intracellular collagen
degradation pathways operate at least partially independent of
each other. This raises the intriguing possibility that pharmaco-
logical inhibition of MMP activity, which is aimed at prevent-
ing pathological connective tissue destruction during cancer
and other degenerative diseases, may be functionally counter-
acted by increased uPARAP/Endo180-dependent intracellular
collagen degradation. The profound increase in intracellular
collagen in connective tissue cells of mice with genetic abla-
tion of the mesenchymal collagenase MMP-14 would support
this notion (Holmbeck et al., 1999).
Materials and methods
Transgenic mice
The study was performed in accordance with animal care guidelines from
the National Institutes of Health. The generation of uPARAP/Endo180
 / 
mice in a mixed C57/129 background has been described previously (En-
gelholm et al., 2003). The mice were backcrossed for five generations to
FVB/N (The Jackson Laboratory). Next, the mice were crossed with FBN/
V-TgN (MMTVPyVT) 634Mu1 (PymT) mice (The Jackson Laboratory) that
were predisposed to malignant mammary adenocarcinoma as a result of
the mammary gland–directed expression of a PymT oncogene (Guy et al.,
1992). uPARAP/Endo180
 / /PymT
  and uPARAP/Endo180
 / /PymT
 
male mice were crossed with uPARAP/Endo180
 /  female mice to gener-
ate study cohorts of littermate and sibling uPARAP/Endo180
 / /PymT
 ,
uPARAP/Endo180
 / /PymT
 , and uPARAP/Endo180
 / /PymT
  virgin fe-
male mice that were 98.4% congenic to FVB. Mice were genotyped by
PCR from ear snip biopsies at weaning as described previously (Bugge et
al., 1998), and the genotype of all mice was reconfirmed at the termina-
tion of the experiment. Each mammary gland of the mice in the study co-
horts was palpated weekly, beginning at weaning, for the formation of
mammary tumors by an investigator who was unaware of animal geno-
type. Mice were killed at the termination of the experiment, and the total
mammary tumor burden was determined as the cumulative weight of each
tumor dissected from the mammary gland by an investigator who was un-
aware of animal genotype.
Tumor explant cultures and collagen internalization assays
Tumor-bearing mice were anesthetized by a brief inhalation of CO2 and
were perfused intracardially with 10 ml of ice-cold PBS. Sections of tumors
( 1 mg) from the left inguinal mammary gland were aseptically removed,
finely minced with a scalpel and scissors, and washed with DME/Ham’s
F12 (1:1; 100 U/ml penicillin and 100 U/ml streptomycin). The minced
tumor tissue was incubated for 40 min at 37 C with continuous agitation
in 5 ml of a solution containing 2.5 mg/ml trypsin (GIBCO BRL) and 850
U/ml of type II collagenase (GIBCO BRL) in PBS containing 5 mg/ml BSA.
The enzymatic action was terminated by adding 1 vol DME/Ham’s F12
containing 5% FCS. The resultant cell suspension was washed once in
DME/Ham’s F12 and plated on poly-D-lysine–coated glass coverslips.
The mixed tumor–stromal explants were maintained in DME/Ham’s F12
containing 5% FCS in a tissue culture incubator at 5% CO2.
For collagen internalization experiments, the mixed tumor–stromal
explants were incubated for 1 h with 20  M E64d (Calbiochem) at 37 C,
and 25  g/ml of Oregon green 488 collagen IV (Molecular Probes) was
added. For time course experiments, Oregon green 488 collagen IV was
added for 30 min at 4 C, and unbound collagen was washed away. 50
nM LysoTracker (Molecular Probes) and DAPI were added 1 h before the
end of the experiment to visualize the lysosomes and nuclei, respectively.
For visualization of cytokeratin by immunofluorescence analysis, Lyso-
Tracker was omitted, and the cells were fixed at the termination of the
experiment with 4% PFA in PBS for 20 min. The coverslips were blockedJCB • VOLUME 169 • NUMBER 6 • 2005 984
with 100 mM glycine followed by 1% BSA in PBS and were incubated with
cytokeratin antibodies (Abcam) followed by rhodamine-conjugated donkey
anti–rabbit (1:200; Jackson ImmunoResearch Laboratories). DAPI (Vector
Laboratories) was added to visualize nuclei. Confocal images were col-
lected on a confocal system (model TCS SP2; Leica) using an upright micro-
scope (model DM-RE-7; Leica) and a 63  1.32 NA objective. Projection
images from the resulting files were made using the LCS software (Leica).
Transmission EM
Tumor-bearing mice were perfused intracardially with ice-cold PBS. Mam-
mary tumors were dissected into 1-mm
3 pieces and were fixed overnight in
2.5% glutaraldehyde and 2% PFA in 0.1 M sodium cacodylate buffer, pH
7.4, at 4 C. The samples were postfixed with 1% OsO4 for 2 h in the
dark, followed by dehydration and embedding. The blocks were polymer-
ized at 68 C for 48 h. Sections were mounted on copper grids and were
stained with uranyl acetate and lead citrate. The sections were then sub-
jected to an exhaustive analysis for intracellular collagen inclusions by us-
ing a transmission electron microscope (model 1010; JEOL) operated at
80 kEV.
Histological analysis
Tumor-bearing mice were anesthetized by a brief inhalation of CO2 and
were perfused intracardially with 10 ml of ice-cold PBS, followed by 10 ml
of 4% PFA in PBS (Electron Microscopy Sciences). The tumors were ex-
cised, bisected along the longest axis, and were either embedded in opti-
mal cutting temperature and immediately frozen in liquid N2 or were fixed
for 24 h in 20 vol of 4% PFA in PBS and processed into paraffin. Immuno-
staining was performed with a Vectastain ABC peroxidase kit (Vector Lab-
oratories) using DAB as the chromogenic substrate. Collagen type I telo-
peptides were detected with LF-67 rabbit polyclonal antiserum (Bernstein et
al., 1996); collagen type I propeptides with LF-41 antibodies (Fisher et al.,
1989); decorin with LF-113 rabbit anti–mouse decorin pAb (Fisher et al.,
1995; all were provided by L. Fisher, National Institute of Dental and
Craniofacial Research, Bethesda, MD); type IV collagen telopeptides with
rabbit pAb (Abcam); nidogen with rat anti–mouse nidogen mAb (BD Bio-
sciences); and fibronectin with rabbit pAb (Santa Cruz Biotechnology,
Inc.), using 5–8- m cryostat sections. Sections were counterstained with
Mayer’s hematoxylin (Zymed Laboratories). For unbiased quantitative his-
tomorphometric analysis of collagen and fibronectin, random low magnifi-
cation (10 ) micrographs of tumors were collected as TIFF files. The frac-
tion of antigen-positive pixels relative to the total field area was determined
with MetaMorph version 5.0r7 software (Universal Imaging Corp.) by us-
ing the threshold image function. The threshold area corresponding to anti-
gen-positive regions was then assessed, and the percent coverage of the
total image area was calculated by using the region measurement ability in
the software. All measurements were performed by an investigator who
was unaware of mouse genotype. Endothelial cells were stained with rat
anti–mouse CD31 (PECAM-1; BD Biosciences), and macrophages were
detected with rat anti–mouse F4/80 (Caltag Laboratories) using 5–8- m
paraffin sections and procedures as described above. Quantitation of ves-
sel and macrophage densities was performed by an investigator who was
unaware of animal genotype by using an ocular grid and a 40  objec-
tive, counting 25 fields from five tumors of each genotype. For uPARAP/
Endo180 immunohistochemistry, paraffin sections were proteolytically di-
gested with proteinase K. Affinity-purified rabbit pAb against mouse
uPARAP/Endo180 were incubated at 0.5 mg/ml overnight at 4 C. The
next day, they were detected with Envision-Rabbit reagent (DakoCytomation),
followed by signal amplification for 5 min using biotinyl tyramine (NEN
Life Science Products) and streptavidin-HRP for 30 min and were incubated
with NovaRed substrate for 10 min. For the determination of proliferation
rates, tumor-bearing mice were injected with BrdU 2 h before they were
killed, and cell proliferation was visualized by staining with BrdU antibod-
ies. Apoptotic nuclei were visualized by TUNEL staining using an Apotag
kit (Intergen) as recommended by the manufacturers. Quantification of pro-
liferating cells and apoptotic nuclei was performed by an investigator who
was unaware of animal genotype by using an ocular grid and a 40  ob-
jective, counting 10 random sections per tumor. Proliferative and apoptotic
indices were determined as the fraction of BrdU-positive cells or apoptotic
nuclei as a percentage of total cells in each section.
In situ hybridization
uPARAP/Endo180 in situ hybridization was performed exactly as de-
scribed previously (Engelholm et al., 2001b) by using two sets of nonover-
lapping sense and antisense uPARAP/Endo180 cDNA probes. MT1-MMP
and MMP-13 in situ hybridization were performed essentially as described
previously (Blavier et al., 2001). In brief, paraffin sections that were pre-
pared as described above were dewaxed in xylene, rehydrated through
a series of ethanol solutions of decreasing concentrations, treated with
5  g/ml proteinase K, postfixed in 4% PFA in PBS, acetylated in triethano-
lamine hydrochloride/acetic anhydride, washed in PBS, dehydrated, and
air dried. The sections were incubated overnight at 50 C in hybridization
buffer containing a single-stranded riboprobe that was radiolabeled with
33P-UTP (PerkinElmer) and complementary sense probes. For the detection
of MT1-MMP mRNA, a probe containing nt 291–902 of the published
MT1-MMP cDNA (GenBank/EMBL/DDBJ under accession no. X83536)
was used, and for the detection of MMP-13, a probe containing nt 1236–
1903 of the murine MMP-13 cDNA (GenBank/EMBL/DDBJ under acces-
sion no. X66473) was used (both were provided by L. Blavier, National
Institutes of Health, Bethesda, MD). After hybridization, the sections were
washed extensively, dehydrated, and air dried. The slides were then
dipped in photographic emulsion (Hypercoat LM-1; Amersham Bio-
sciences) and were exposed for 3–5 d at 4 C. After exposure, the slides
were developed and counterstained with Mayer’s hematoxylin.
Northern blot analysis
Tumor-bearing mice were anesthetized by a brief inhalation of CO2 and
perfused intracardially with 10 ml of ice-cold PBS. Mammary tumors were
excised, snap-frozen in liquid nitrogen, and ground to a fine powder with
a mortar and pestle. Total RNA was prepared by extraction in TRIzol re-
agent (GIBCO BRL), as recommended by the manufacturers. 10  g of
RNA samples were fractionated electrophoretically on formaldehyde aga-
rose gels, blotted onto NytranSuperCharge nylon membranes (Schleicher
& Schuell), and hybridized to PCR-generated 
32P-labeled murine Col1A1
(nt 3648–3879 from Genbank/EMBL/DDBJ under accession no.
007742; amplified by using the primers 5 -CGGTTATGACTTCAGCT-
TCCTGCC-3  and 5 -GCTCTTCCAGTCAGAGTGGCACAT-3 ), Col4A1
(nt 6002–6188 from GenBank/EMBL/DDBJ under accession no.
BC072650.1; amplified using the primers 5 -GGAGCTGGGAAGTTGC-
CTGTGTG-3  and 5 -ATAATGAGCCCTGTGCCTGGCGC-3 ), or a full-
length murine GAPDH cDNA probe. Membranes were exposed to Phos-
phorImage screens and hybridization signals that were quantitated with
ImageQuant software (Molecular Dynamics).
Gelatin zymography and reverse zymography
Tumors were frozen in liquid nitrogen and homogenized in PBS with a
Dounce homogenizer (model 1984-100-15; Bellco Biotechnology). The
homogenate was centrifuged at 25,000 g for 30 min, and the pellet was
resuspended in PBS with sonication. SDS was added to a final concentra-
tion of 1%, and the samples were mixed gently at RT for 1.5 h. The sam-
ples were spun again, and the amount of protein in the supernatants was
determined by bicinchoninic acid protein assay (Pierce Chemical Co.).
Equal amounts of protein were loaded onto a gelatin zymogram (Invitro-
gen), and the zymogram was run and developed according to the manu-
facturer’s instructions. For reverse zymography, equal amounts of protein
were loaded on 17% polyacrylamide reverse zymogram gels prepared
with 2.5 mg/ml gelatin and 0.075  g/ml gelatinase A. The zymograms
were developed for 30 h at 37 C in 50 mM Tris, pH 7.4, 0.2 M NaCl,
5 mM CaCl2, and 0.02% (wt/vol) Brij-35.
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